Abstract:Protein bioconjugation has become an increasingly important research method for introducing artificial functions in to protein with various applications, including therapeutics and biomaterials. Due to its amphiphilic nature, only a few tyrosine residues are exposed on the protein surface. Therefore, tyrosine residue has attracted attention as suitable targets for site-specific modification, and it is the most studied amino acid residue for modification reactions other than lysine and cysteine residues. In thi… Show more
“…To overcome the heterogeneity drawback of current ADCs, several site-specific and chemical conjugation methodologies have emerged in recent decades. , Utilizing Fc-affinity binders is a promising approach for the construction of site-specific ADCs . This novel conjugation method offers several advantages, such as not requiring antibody engineering and avoiding the use of enzymes, which can be challenging to remove after conjugation. − However, as this technology is mainly used at the research stage, the challenge of developing scalable and robust manufacturing processes using Fc-affinity reagents remains. The limited scope of Fc-affinity technologies for site-specific ADC generation prompted us to develop a versatile and facile direct antibody modification technology that circumvents antibody engineering .…”
Chemical
site-specific conjugation technology utilizing immunoglobulin-G
(IgG) Fc-affinity reagents is a versatile and promising tool for producing
next-generation antibody–drug conjugates (ADCs). Our research
group recently reported a novel Fc-affinity peptide-mediated conjugation
method, termed AJICAP second-generation. This technology, based on
thioester chemistry, produces site-specific ADCs with low aggregation.
Herein, we report further investigations into the AJICAP second-generation
technology. By varying the parameters of the peptide conjugation step,
it was found that this reaction is feasible under a wide range of
reaction conditions. All synthetic intermediates of the AJICAP-ADCs
were sufficiently stable, indicating that each synthetic step is a
possible holding point in ADC manufacturing. The Lys248- and Lys288-conjugated
ADCs were prepared on a gram-scale using two different Fc-affinity
peptide reagents, employing a scale-down manufacturing approach involving
tangential flow filtration. The overall product yield was >80%,
and
ultimately, 13.2 g of trastuzumab-Lys248-MMAE and 1.26 g of trastuzumab-Lys288-MMAE
were obtained with target drug to antibody ratios (DARs). Moreover,
ADCs were synthesized at various scales, and it was verified that
the DAR and aggregation rates could be replicated consistently across
different scales. The results strongly indicate that the AJICAP second-generation
process is a robust and practical approach for the manufacture of
ADCs.
“…To overcome the heterogeneity drawback of current ADCs, several site-specific and chemical conjugation methodologies have emerged in recent decades. , Utilizing Fc-affinity binders is a promising approach for the construction of site-specific ADCs . This novel conjugation method offers several advantages, such as not requiring antibody engineering and avoiding the use of enzymes, which can be challenging to remove after conjugation. − However, as this technology is mainly used at the research stage, the challenge of developing scalable and robust manufacturing processes using Fc-affinity reagents remains. The limited scope of Fc-affinity technologies for site-specific ADC generation prompted us to develop a versatile and facile direct antibody modification technology that circumvents antibody engineering .…”
Chemical
site-specific conjugation technology utilizing immunoglobulin-G
(IgG) Fc-affinity reagents is a versatile and promising tool for producing
next-generation antibody–drug conjugates (ADCs). Our research
group recently reported a novel Fc-affinity peptide-mediated conjugation
method, termed AJICAP second-generation. This technology, based on
thioester chemistry, produces site-specific ADCs with low aggregation.
Herein, we report further investigations into the AJICAP second-generation
technology. By varying the parameters of the peptide conjugation step,
it was found that this reaction is feasible under a wide range of
reaction conditions. All synthetic intermediates of the AJICAP-ADCs
were sufficiently stable, indicating that each synthetic step is a
possible holding point in ADC manufacturing. The Lys248- and Lys288-conjugated
ADCs were prepared on a gram-scale using two different Fc-affinity
peptide reagents, employing a scale-down manufacturing approach involving
tangential flow filtration. The overall product yield was >80%,
and
ultimately, 13.2 g of trastuzumab-Lys248-MMAE and 1.26 g of trastuzumab-Lys288-MMAE
were obtained with target drug to antibody ratios (DARs). Moreover,
ADCs were synthesized at various scales, and it was verified that
the DAR and aggregation rates could be replicated consistently across
different scales. The results strongly indicate that the AJICAP second-generation
process is a robust and practical approach for the manufacture of
ADCs.
“…Due to the modification of protein complex system by ultrasound is random and extensive, when the protein complex system is subjected to specific treatment, it is often compounded with chemical field and biological field, because the directional modification ability of chemical field and biological field will be stronger. For example: Sato [35] reviewed the research progress of chemical modification of tyrosine, a method of modifying histidine by singlet oxygen produced by photosensitizer has been developed, which has been proved to be highly selective. Similar to enzyme reaction, enzyme as a protein molecule participates in the modification process of protein composite system.…”
Section: Influence Mechanism Of Ultrasound and Its Composite Field On...mentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.